Publication | Open Access
OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
38
Citations
0
References
2021
Year
MedicineImmunologyPathologyLcmc3 StudyImmune Checkpoint InhibitorCancer TreatmentMolecular DiagnosticsOncologyRadiation OncologyMolecular OncologyOa06.06 Clinical/biomarker DataNeoadjuvant Atezolizumab
No additional data available for this publication yet. Check back later!